A global investment banking boutique serving companies in the life sciences industry. Since our inception in 2007, we have advised clients on more than $100 billion worth of deals for biotechnology, branded pharmaceutical, generic pharmaceutical, and life sciences companies. Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks. We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, pharmaceutical asset sale, capital markets, and licensing transactions. Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence. Over half the transactions on which we advise are cross-border. Torreya has offices in London, Mumbai, and New York, and affiliate offices on six continents.
Novo Ventures is a global team of investment professionals employed by Novo affiliates that supports Novo Holdings’ investments in private, public and structured product opportunities in the life sciences industry. Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding and investment company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Foundation’s assets. Novo Holdings is recognized as a world-leading life science investor with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 29 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide. PharmaVentures' deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest. PharmaVentures’ services include:
M&A (divestments, mergers, acquisitions, and strategic transactions)
Licensing (in and out licensing)
Strategy (commercialisation, deal strategy, due diligence, market entry)
Valuation and Positioning (licensing, M&A, and fundraising)
PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific. PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).
TVM Capital Life Science is a group of independent investment advisories and fund managers for Venture Capital funds, investing into innovative biotech, pharmaceutical, and medtech companies with teams based in Munich and Montreal. Since 1984, TVM Capital Life Science has invested in more than 140 life science companies in Europe, Canada and the United States, currently managing in excess of US$1.1 billion from more than 50 investors.